Boston Scientific Cuts 2026 EPS Outlook, Warns of 2027 Growth Pressure

Why did Boston Scientific lower its 2026 earnings forecast?

Competition in electrophysiology, softer Watchman implant demand and China's medical-device price cuts weakened performance, while an August cybersecurity disruption reduced third-quarter adjusted EPS by an estimated $0.07.

Orbitrum Investor Impact

What did Boston Scientific's third-quarter results show?

Third-quarter revenue increased 1.5% to $5.138 billion, but adjusted EPS declined to $0.73 from $0.75 a year earlier, showing that modest sales growth was not translating into higher adjusted earnings.

Why does the slowdown matter for Boston Scientific's business?

Weaker electrophysiology and Watchman sales are creating an unfavorable product mix, while Chinese price reductions are squeezing gross margins, making revenue and adjusted earnings growth difficult in 2027 even with restructuring savings.

How could the weaker outlook affect Boston Scientific stock?

Lower earnings expectations and the risk of prolonged margin pressure could weigh on the valuation of Boston Scientific shares (NYSE: BSX); Reuters reported that the stock was down 5.3% during afternoon trading on October 28.

How does the Penumbra acquisition affect the 2027 outlook?

Management's warning about difficult 2027 growth excludes its pending $14.5 billion Penumbra acquisition, now expected to close in the first quarter of 2027 after extended regulatory reviews, while higher financing costs could increase the transaction's initial earnings dilution.

What should Boston Scientific investors watch next?

Fourth-quarter 2026 results will test management's forecast of a 1%–3% year-over-year sales decline and adjusted EPS of $0.77–$0.79, followed by detailed 2027 guidance clarifying the expected duration of heart-device and Chinese pricing pressures.